ELIZABETH MCCUSKER-HUNT: Open Payments
NPI 1770597429 · AMESBURY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,756 in 78 payments from 11 companies in 2025. Trend: 2023 $1,612 · 2024 $1,497 · 2025 $1,756
Food & beverage: $1,644Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $412 |
| E.R. Squibb & Sons, L.L.C. | 16 | $386 |
| Alkermes, Inc. | 12 | $246 |
| ABBVIE INC. | 12 | $226 |
| Teva Pharmaceuticals USA, Inc. | 10 | $219 |
| Neurocrine BioSciences, Inc. | 2 | $68 |
| Vanda Pharmaceuticals Inc. | 4 | $65 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: CAPLYTA, COBENFY, VRAYLAR, ARISTADA, LYBALVI, INGREZZA, FANAPT, REXULTI.
Industry payments across MA — which companies pay providers there.
